Panagora Asset Management’s Immunovant IMVT Stock Holding History

Panagora Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-820	Closed	-$8K	–	2512
2019 Q3	$8K	Buy	+820	New	+$8.09K	﹤0.01%	2210

Other funds holding IMVT

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Athanor Capital New York $24.6M AUM 2.49% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Panagora Asset Management's IMVT Position: Q4 2019 in Review

Panagora Asset Management sold out of Immunovant (IMVT) in Q4 2019, closing a stake of 820 shares — an estimated $8K sold.

Panagora Asset Management first reported a position in IMVT in Q3 2019 and held it in 1 quarter. The position peaked at $8K in Q3 2019. 24 funds tracked by Wall St. Rank hold IMVT as of Q4 2019.

Panagora Asset Management reported no remaining Immunovant position as of Q4 2019 after selling out during the quarter.
Panagora Asset Management sold 820 Immunovant shares in Q4 2019, an estimated $8K.
Panagora Asset Management first reported a position in Immunovant in Q3 2019 and held it in 1 quarter.
Panagora Asset Management's Immunovant position peaked at $8K in Q3 2019.
24 funds tracked by Wall St. Rank held Immunovant as of Q4 2019.

Based on Panagora Asset Management's 13F filing for Q4 2019, filed 12 Feb 2020.